JRCT ID: jRCT2080224888
Registered date:26/09/2019
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 30/10/2019 |
Target sample size | 9 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | safety safety safety safety pharmacokinetics |
---|---|
Secondary Outcome | efficacy efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Astellas Pharma Inc. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04094506,JapicCTI-194973 |
Contact
Public contact | |
Name | Medical Information Center |
Address | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo |
Telephone | +81-120-189-371 |
clinicaltrialregistration@astellas.com | |
Affiliation | Astellas Pharma Inc. |
Scientific contact | |
Name | |
Address | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo |
Telephone | +81-120-189-371 |
clinicaltrialregistration@astellas.com | |
Affiliation | Astellas Pharma Inc. |